New Results

A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model

Lucie Jelínková, Yevel Flores-Garcia, Sarah Shapiro, Bryce T. Roberts, Nikolai Petrovsky, Fidel Zavala, Bryce Chackerian
doi: https://doi.org/10.1101/2021.11.10.465032

Article Information

doi 
https://doi.org/10.1101/2021.11.10.465032
History 
  • November 11, 2021.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Lucie Jelínková1,
  2. Yevel Flores-Garcia2,
  3. Sarah Shapiro2,
  4. Bryce T. Roberts1,
  5. Nikolai Petrovsky3,4,
  6. Fidel Zavala2 and
  7. Bryce Chackerian1,*
  1. 1Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA
  2. 2W. Harry Feinstone Department of Molecular Microbiology and Immunology Malaria Research Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  3. 3Vaxine Pty Ltd., 11 Walkley Avenue, Warradale, Adelaide 5046, Australia
  4. 4College of Medicine and Public Health, Flinders University, Adelaide 5042, Australia
  1. ↵*Corresponding author: bchackerian{at}salud.unm.edu
Back to top
Posted November 11, 2021.
Download PDF
Email
A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model
Lucie Jelínková, Yevel Flores-Garcia, Sarah Shapiro, Bryce T. Roberts, Nikolai Petrovsky, Fidel Zavala, Bryce Chackerian
bioRxiv 2021.11.10.465032; doi: https://doi.org/10.1101/2021.11.10.465032
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area